XML 50 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
General and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventories consist of the following (in thousands):
As of December 31,
 20242023
Raw materials$265,275 $296,037 
Work in process37,528 58,906 
Finished goods281,873 354,417 
Total$584,676 $709,360 
_____________________________
As of December 31, 2024, inventory account balances that are part of a disposal group that met the criteria for assets held for sale during the fourth quarter of 2024 were combined with other disposal group assets and presented as a separate line item "Assets Held For Sale" in our consolidated balance sheet (See Note 4:Assets Held For Sale).
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment consists of the following (in thousands): 
As of December 31,
 20242023
Machinery and equipment(1)
$400,861 $483,382 
Land, building and building improvements(1)
177,089 278,251 
Molds96,318 89,573 
Computer equipment and software(1)
122,208 122,038 
Furniture and fixtures(1)
27,871 30,662 
Instruments placed with customers(2)
124,290 115,672 
Construction in progress(1)
87,006 117,219 
Total property, plant and equipment, cost1,035,643 1,236,797 
Accumulated depreciation(1)
(592,897)(623,888)
Property, plant and equipment, net (1)
$442,746 $612,909 
_______________________________
(1)     As of December 31, 2024, certain property, plant and equipment category account balances that are part of a disposal group that met the criteria for assets held for sale during the fourth quarter of 2024 were combined with other disposal group assets and presented as a separate line item "Assets held For Sale" in our consolidated balance sheet, $99.4 million of accumulated depreciation was included in the disposal group and reclassified to assets held for sale. See Note 4: Assets Held For Sale.
(2)    Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives.  Estimated useful lives are:
Buildings
15 - 30 years
Building improvements
15 - 30 years
Machinery and equipment and molds
2 - 15 years
Furniture, fixtures and office equipment
2 - 5 years
Computer equipment and software
3 - 5 years
Instruments placed with customers
3 - 10 years
Schedule of Goodwill
The following table presents the changes in the carrying amount of our goodwill for 2024, 2023 and 2022 (in thousands):
Total
Balance as of January 1, 2022$43,439 
Goodwill(1)
1,469,880 
Other(2)
(7,128)
Disposition(3)
(650)
Currency translation(56,283)
Balance as of December 31, 20221,449,258 
Currency translation23,188 
Balance as of December 31, 20231,472,446 
Currency translation(39,674)
Balance as of December 31, 2024$1,432,772 
_______________________________
(1)    Relates to Smiths Medical acquired on January 6, 2022 (see Note 2: Acquisitions).
(2)    Reflects a measurement period adjustment related to the 2021 acquisition of a small foreign infusion systems supplier.
(3)    Relates to the sale of a certain line of infusion products in China.
Schedule of Indefinite-Lived Intangible Assets
Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):
 Weighted-Average Amortization Life
in Years		December 31, 2024
 CostAccumulated
Amortization		Net
Patents10$36,811 $22,913 $13,898 
Customer contracts129,818 6,994 2,824 
Non-contractual customer relationships8546,404 236,267 310,137 
Trademarks15,425 5,425 — 
Trade name1518,239 8,357 9,882 
Developed technology(1)
10619,540 227,869 391,671 
Non-compete39,100 9,100 — 
    Total amortized intangible assets $1,245,337 $516,925 $728,412 
Internally developed software(2)
$12,377 $12,377 
Total intangible assets$1,257,714 $516,925 $740,789 
_______________________________
(1)    Developed technology primarily consists acquired patented technologies and internally developed software. Upon completion of development, the assets will be amortized over their estimated useful lives.
(2)    Internally developed software will be reclassified to developed technology and amortized when the projects are complete and the assets are ready for their intended use. During 2024, we reclassified $33.2 million to developed technology.

 Weighted-Average Amortization Life
in Years		December 31, 2023
 CostAccumulated
Amortization		Net
Patents10$33,261 $20,637 $12,624 
Customer contracts1210,018 6,755 3,263 
Non-contractual customer relationships8554,982 171,279 383,703 
Trademarks15,425 5,425 — 
Trade name1518,251 7,162 11,089 
Developed technology10587,852 167,913 419,939 
Non-compete39,100 7,450 1,650 
Total amortized intangible assets $1,218,889 $386,621 $832,268 
Internally developed software*$38,320 $38,320 
Total intangible assets$1,257,209 $386,621 $870,588 
_______________________________
* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
As of December 31, 2024, estimated annual amortization for our intangible assets for each of the next five years and thereafter is approximately (in thousands):
2025$129,604 
2026127,612 
2027117,450 
2028116,852 
2029113,775 
Thereafter123,119 
Total$728,412 
Debt Securities, Available-for-sale
As of December 31, 2023
Amortized CostUnrealized Holding Gains (Losses)Fair Value
Short-term corporate bonds$501 $— $501 
Schedule of Available-for-Sale Securities Reconciliation
As of December 31, 2024, we did not have any investment securities. As of December 31, 2023, the amortized cost, unrealized holding gains (losses) and fair value of our available-for-sale investment securities were as follows (in thousands):
As of December 31, 2023
Amortized CostUnrealized Holding Gains (Losses)Fair Value
Short-term corporate bonds$501 $— $501 
Equity Method Investments
Our non-marketable equity method investment consists of the following (in thousands):

As of December 31,
20242023
Equity method investment$3,038 $3,120 
Interest Income and Interest Expense Disclosure
Interest expense, net

The following table presents interest (expense) income, net (in thousands): 
As of December 31,
202420232022
Interest expense$(106,541)$(102,727)$(70,805)
Interest income10,788 7,508 4,430 
Interest expense, net$(95,753)$(95,219)$(66,375)
Schedule of Other Nonoperating Income (Expense)
Other expense, net

The following table presents other expense, net (in thousands): 
As of December 31,
202420232022
Foreign exchange losses, net$(9,792)$(5,918)$(5,780)
Loss on disposition of assets(1,608)(153)(2,554)
Other miscellaneous (expense) income, net(1,823)166 3,198 
Other expense, net$(13,223)$(5,905)$(5,136)
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data): 
 Year ended December 31,
 202420232022
Net loss$(117,688)$(29,655)$(74,286)
Weighted-average number of common shares outstanding (basic)24,388 24,091 23,868 
Dilutive securities— — — 
Weighted-average common and common equivalent shares outstanding (diluted)24,388 24,091 23,868 
EPS — basic$(4.83)$(1.23)$(3.11)
EPS — diluted$(4.83)$(1.23)$(3.11)
Total anti-dilutive stock options and restricted stock awards (shares in thousands)
42 129 141